Molecular targeting important players in GBM could be an alternative to tackle this disease, and receptor tyrosine kinases (RTKs) such as EGFR and Platelet Derived Growth Factor Receptor Alpha (PDGFRA) have been considered as targets in trials using small molecule inhibitors, because apart from harbouring mutations, the corresponding genes are frequently amplified [2,3]. The gene discussed is PDGFRA; the disease is glioblastoma.